Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction

Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.